News
After two failed IPOs, Mapi Pharma raised €9 Million from private ...www.labiotech.eu › News and Trends
www.labiotech.eu
In fact, Mapi's candidate is a derived version of TEVA's Copaxone, in which Ehud Marom, founder and CEO of Mapi Pharma, worked during his time at TEVA.
Mapi Pharma to Present Series of Recent Advancements for
www.globenewswire.com
Ehud Marom, Chairman and Chief Executive Officer of Mapi, said, “Mapi is working to be the leading MS Company with a long acting GA Depot ...
Biodar Acquires the Activities Of Karma Pharm | New Hope Network
www.newhope.com
Founders to receive US $2 million plus stock Yavne, Israel, 22 of January Biodar Ltd, a subsidiary of Lycored
First Patient Treated in Mapi Pharma’s Phase II Clinical
www.globenewswire.com
Study is being conducted on strength of prior Phase II clinical trial that showed strong efficacy in RRMS patients who switched from Copaxone® to...
sortiert nach Relevanz / Datum